All In MedTech

Device Trial Radar · NCT06735833

MMA Embolization for Refractory Chronic Migraine

Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Actual

Start

Apr 23, 2025

Primary completion

Dec 25, 2026

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 16, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Conditions

  • Migraine Disorders

Interventions

  • Middle Meningeal Artery embolizationDevice

    Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline, in number of migraine daysTime frame: over 28 days post study intervention

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • John Muir Physician Network Clin. Research Center

    Walnut Creek, California

  • Hartford Hospital

    Hartford, Connecticut

  • University of Buffalo Medical Center

    Buffalo, New York

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.